Home
News
Create
Screeners
Insights
ANG Lifesciences
32.
97
-1.34
(-3.91%)
Market Cap
₹43.05 Cr
PE Ratio
-3.81
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-3.91%
1M
+70.74%
6M
+0.86%
1Y
+22.79%
5Y
-30.74%
View Company Insights
Latest news about ANG Lifesciences
ANG Lifesciences India Limited Confirms Non-Applicability of SEBI Large Corporate Borrowing Requirements for FY26
Apr 17, 2026
ANG Lifesciences India Limited has informed BSE that it does not qualify as a Large Corporate for FY26, making SEBI borrowing requirements and annual disclosure obligations non-applicable. The company referenced multiple regulatory circulars and committed to future compliance if it meets Large Corporate criteria.
ANG Lifesciences India Limited Submits SEBI Compliance Certificate for Q4 FY26
Apr 15, 2026
ANG Lifesciences India Limited Responds to BSE Query on Recent Price Movement
Apr 10, 2026
ANG Lifesciences Reports Q3 FY26 Financial Results with Detailed Performance Metrics
Feb 15, 2026
ANG Lifesciences India Limited Schedules Board Meeting for February 14, 2026 to Consider Q3FY26 Financial Results
Feb 05, 2026
More news about ANG Lifesciences
15
Nov 25
ANG Lifesciences Reports Q2 FY2026 Loss, Appoints New Cost Auditor
ANG Lifesciences India Limited reported a reduced net loss of ₹79.98 lakh in Q2 FY2026, down from ₹107.39 lakh in Q2 FY2025. However, revenue from operations decreased to ₹2597.05 lakh from ₹3215.88 lakh year-over-year. For H1 FY2026, the net loss improved to ₹158.71 lakh from ₹383.92 lakh in the previous year. The company's Board approved the appointment of M/s Shreya Sahu & Associates as Cost Auditor for FY2025-26.
ANG Lifesciences
32.
97
-
1.
34
(-
3.
91
%)
1 Year Returns:
+22.79%
Industry Peers
Sun Pharmaceutical
1,778.70
(+
1.
80
%)
Divis Laboratories
6,534.00
(+
1.
58
%)
Torrent Pharmaceuticals
4,231.50
(+
1.
16
%)
Dr Reddys Laboratories
1,329.80
(-
1.
83
%)
Cipla
1,317.60
(+
0.
85
%)
Lupin
2,311.40
(+
0.
38
%)
Mankind Pharma
2,256.80
(-
0.
34
%)
Zydus Life Science
910.85
(-
0.
05
%)
Aurobindo Pharma
1,396.80
(-
1.
81
%)
Glenmark Pharmaceuticals
2,413.90
(+
0.
42
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO